IDXX - IDEXX Laboratories Inc Stock Price, Fair Value and News

498.89USD-6.45 (-1.28%)Delayed as of 30 Apr 2024, 11:55 am ET

Market Summary

USD498.89-6.45

Delayedas of 30 Apr 2024, 11:55 am

-1.28%

IDXX Stock Price

View Fullscreen

IDXX RSI Chart

IDXX Valuation

Market Cap

42.0B

Price/Earnings (Trailing)

49.69

Price/Sales (Trailing)

11.47

EV/EBITDA

34.62

Price/Free Cashflow

54.33

IDXX Price/Sales (Trailing)

IDXX Profitability

Operating Margin

59.82%

EBT Margin

28.99%

Return on Equity

56.92%

Return on Assets

25.92%

Free Cashflow Yield

1.84%

IDXX Fundamentals

IDXX Revenue

Revenue (TTM)

3.7B

Rev. Growth (Yr)

8.81%

Rev. Growth (Qtr)

-1.52%

IDXX Earnings

Earnings (TTM)

845.0M

Earnings Growth (Yr)

12.96%

Earnings Growth (Qtr)

-8.34%

Breaking Down IDXX Revenue

52 Week Range

420.22564.74

(Low)(High)

Last 7 days

5.4%

Last 30 days

-6.4%

Last 90 days

-3.0%

Trailing 12 Months

2.7%

How does IDXX drawdown profile look like?

IDXX Financial Health

Current Ratio

1.57

Debt/Equity

0.42

Debt/Cashflow

1.46

IDXX Investor Care

Shares Dilution (1Y)

0.22%

Diluted EPS (TTM)

10.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.4B	3.5B	3.6B	3.7B
2022	3.3B	3.3B	3.3B	3.4B
2021	2.9B	3.0B	3.1B	3.2B
2020	2.5B	2.5B	2.6B	2.7B
2019	2.3B	2.3B	2.4B	2.4B
2018	2.0B	2.1B	2.2B	2.2B
2017	1.8B	1.9B	1.9B	2.0B
2016	1.6B	1.7B	1.7B	1.8B
2015	1.5B	1.5B	1.6B	1.6B
2014	1.4B	1.4B	1.5B	1.5B
2013	1.3B	1.3B	1.3B	1.4B
2012	1.2B	1.3B	1.3B	1.3B
2011	1.1B	1.2B	1.2B	1.2B
2010	1.1B	1.1B	1.1B	1.1B
2009	0	1.0B	1.0B	1.0B
2008	0	0	0	1.0B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of IDEXX Laboratories Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	polewaczyk james f	acquired	3,423,550	422	8,104	executive vice president
Mar 06, 2024	polewaczyk james f	sold	-4,525,600	558	-8,104	executive vice president
Mar 05, 2024	vandebroek sophie v.	sold	-790,427	562	-1,404	-
Mar 05, 2024	vandebroek sophie v.	acquired	345,089	245	1,404	-
Feb 29, 2024	mazelsky jonathan jay	gifted	-	-	-550	president and ceo
Feb 21, 2024	mazelsky jonathan jay	acquired	99,952	206	483	president and ceo
Feb 16, 2024	underberg sharon e.	acquired	99,952	206	483	evp, gc & corporate secretary
Feb 15, 2024	mckeon brian p	acquired	99,952	206	483	evp, cfo and treasurer
Feb 14, 2024	underberg sharon e.	acquired	-	-	1,186	evp, gc & corporate secretary
Feb 14, 2024	schreck michael	sold (taxes)	-65,585	560	-117	executive vice president

Which funds bought or sold IDXX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	Planning Capital Management Corp	reduced	-65.22	-8,447	4,320	-%
Apr 26, 2024	YOUSIF CAPITAL MANAGEMENT, LLC	reduced	-2.09	-347,808	6,969,420	0.08%
Apr 26, 2024	Dougherty Wealth Advisers LLC	unchanged	-	-2,873	102,587	0.09%
Apr 26, 2024	AustralianSuper Pty Ltd	added	2.62	-100,161	6,297,340	0.04%
Apr 26, 2024	UMB Bank, n.a.	reduced	-79.89	-124,752,000	30,339,200	0.48%
Apr 26, 2024	PINNACLE ASSOCIATES LTD	reduced	-8.79	-129,566	1,019,390	0.02%
Apr 26, 2024	RIVERBRIDGE PARTNERS LLC	reduced	-4.18	-4,383,630	60,204,900	0.74%
Apr 26, 2024	SYSTM Wealth Solutions LLC	added	8.08	141,800	2,904,280	0.37%
Apr 26, 2024	BELLEVUE ASSET MANAGEMENT, LLC	new	-	1,080	1,080	-%
Apr 26, 2024	CONNING INC.	unchanged	-	-7,727	275,904	0.01%

Are Funds Buying or Selling IDXX?

Are funds buying IDXX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IDXX

No. of Funds

Unveiling IDEXX Laboratories Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	10.09%	8,377,667	SC 13G/A
Jan 24, 2024	blackrock inc.	10.9%	9,054,229	SC 13G/A
Dec 08, 2023	vanguard group inc	10.03%	8,331,697	SC 13G/A
Feb 14, 2023	fundsmith llp	5.37%	4,447,828	SC 13G
Feb 14, 2023	fundsmith llp	5.37%	4,447,828	SC 13G
Feb 09, 2023	vanguard group inc	9.82%	8,132,479	SC 13G/A
Jan 26, 2023	blackrock inc.	10.3%	8,502,881	SC 13G/A
Jan 20, 2023	blackrock inc.	10.3%	8,502,881	SC 13G/A
Feb 10, 2022	vanguard group inc	9.34%	7,923,466	SC 13G/A
Jan 27, 2022	blackrock inc.	10.6%	8,990,586	SC 13G/A

Recent SEC filings of IDEXX Laboratories Inc

View All Filings

Date Filed	Form Type	Document
Mar 27, 2024	ARS	ARS
Mar 27, 2024	DEF 14A	DEF 14A
Mar 27, 2024	DEFA14A	DEFA14A
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 04, 2024	4	Insider Trading
Feb 22, 2024	10-K	Annual Report
Feb 22, 2024	4	Insider Trading

Peers (Alternatives to IDEXX Laboratories Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.6B	23.7B	-1.16%	4.18%	41.49	7.69	-8.94%	-35.72%
IDXX	42.0B	3.7B	-6.41%	2.68%	49.69	11.47	8.72%	24.44%
A	40.9B	6.7B	-4.07%	3.07%	33.1	6.07	-2.81%	-6.58%
DGX	14.9B	9.3B	4.80%	0.50%	17.63	1.61	-3.29%	6.68%
MEDP	12.3B	2.0B	-0.97%	99.97%	39.25	6.25	25.57%	21.62%
CRL	11.9B	4.1B	-14.34%	22.08%	25.11	2.89	3.86%	-2.39%
NTRA	11.4B	1.1B	2.82%	85.41%	-26.12	10.49	31.99%	20.63%
EXAS	10.7B	2.5B	-14.89%	-8.26%	-52.27	4.27	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-21.29%	-27.87%	1.7K	2.9	28.93%	111.61%
GH	2.2B	563.9M	-11.83%	-19.37%	-4.62	3.93	25.45%	26.76%
SMALL-CAP
CDNA	424.6M	280.3M	-22.57%	1.36%	-2.23	1.51	-12.89%	-148.37%
ACRS	86.5M	31.2M	-1.61%	-86.28%	-0.98	2.77	5.03%	-1.81%
APDN	65.4M	9.0M	839.02%	296.91%	-9.04	7.27	-53.31%	2.21%
AWH	41.1M	9.2M	7.42%	-36.33%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

IDEXX Laboratories Inc News

Latest updates

IDEXX Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.5%	902	916	944	900	829	842	861	837	801	810	826	778	721	722	638	626	605	605	620	576	549
Cost Of Revenue	2.1%	375	368	371	357	344	335	347	338	345	338	337	307	-	-	-	-	-	-	-	-	249
Gross Profit	-4.0%	526	548	573	543	485	507	514	499	456	473	489	471	410	423	379	360	331	345	358	332	300
S&GA Expenses	4.7%	142	136	141	148	132	130	130	132	128	124	119	115	116	108	94.00	116	106	105	101	107	96.00
R&D Expenses	8.0%	52.00	48.00	47.00	45.00	43.00	48.00	123	40.00	45.00	40.00	38.00	38.00	39.00	38.00	32.00	33.00	35.00	34.00	32.00	32.00	30.00
EBITDA Margin	-0.1%	0.33*	0.33*	0.33*	0.30*	0.30*	0.29*	0.29*	0.32*	0.32*	0.33*	0.32*	0.31*	-	-	-	-	-	-	-	-	-
Interest Expenses	7.1%	9.00	9.00	11.00	13.00	14.00	11.00	8.00	7.00	7.00	7.00	8.00	8.00	8.00	8.00	9.00	8.00	7.00	7.00	8.00	8.00	9.00
Income Taxes	-18.9%	45.00	56.00	62.00	54.00	41.00	53.00	39.00	48.00	29.00	44.00	49.00	36.00	2.00	18.00	35.00	25.00	18.00	24.00	30.00	22.00	21.00
Earnings Before Taxes	-10.5%	240	268	286	268	213	234	171	241	192	219	252	240	177	164	184	137	109	133	156	125	107
EBT Margin	0.5%	0.29*	0.29*	0.28*	0.26*	0.26*	0.25*	0.25*	0.28*	0.28*	0.28*	0.27*	0.27*	-	-	-	-	-	-	-	-	-
Net Income	-8.3%	195	212	224	214	172	181	132	194	163	175	203	204	175	146	149	112	90.00	109	126	103	86.00
Net Income Margin	0.7%	0.23*	0.23*	0.23*	0.20*	0.20*	0.20*	0.20*	0.22*	0.23*	0.24*	0.24*	0.24*	-	-	-	-	-	-	-	-	-
Free Cashflow	-8.8%	217	238	173	144	124	151	36.00	83.00	178	142	211	104	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	5.6%	3,260	3,086	2,871	2,808	2,747	2,640	2,607	2,593	2,437	2,386	2,412	2,327	2,295	2,047	1,961	1,886	1,832	1,751	1,724	1,681	1,537
Current Assets	8.0%	1,495	1,384	1,179	1,149	1,101	1,059	1,043	1,090	956	938	1,001	1,098	1,063	869	780	721	680	703	712	698	654
Cash Equivalents	36.9%	454	332	133	111	113	99.00	114	205	144	145	232	351	384	176	105	81.00	90.00	104	111	117	124
Inventory	-3.5%	380	394	395	391	368	355	333	302	269	258	241	226	210	218	229	212	195	205	197	189	173
Net PPE	2.2%	702	687	683	665	649	612	594	593	588	573	550	544	555	548	551	546	534	497	470	449	437
Goodwill	1.2%	366	362	364	363	362	355	356	361	359	4.00	109	243	243	238	235	23.00	240	25.00	215	215	214
Liabilities	-0.8%	1,775	1,789	1,777	1,967	2,138	2,164	2,150	1,953	1,747	1,630	1,664	1,624	1,662	1,606	1,687	1,778	1,655	1,549	1,553	1,629	1,547
Current Liabilities	-1.9%	952	970	884	1,066	1,236	1,190	1,167	971	764	634	652	621	583	527	541	846	725	627	619	690	770
Long Term Debt	0.7%	623	619	697	696	694	761	768	773	775	778	780	779	858	853	-	-	699	-	-	-	-
LT Debt, Current	-50.0%	75.00	150	75.00	75.00	75.00	-	-	-	75.00	75.00	125	125	50.00	50.00	-	-	-	-	-	-	-
LT Debt, Non Current	0.7%	623	619	697	696	694	761	768	773	775	778	780	779	858	853	-	-	699	-	-	-	-
Shareholder's Equity	14.4%	1,485	1,297	1,094	841	609	476	457	640	690	755	748	703	633	441	273	108	178	203	172	52.00	-
Retained Earnings	4.6%	4,445	4,250	4,038	3,814	3,600	3,427	3,246	3,114	2,920	2,758	2,582	2,380	2,176	2,001	1,855	1,706	1,596	1,505	1,396	1,271	1,168
Additional Paid-In Capital	1.7%	1,570	1,543	1,515	1,490	1,463	1,438	1,420	1,400	1,377	1,359	1,339	1,321	1,295	1,274	1,247	1,230	1,214	1,190	1,171	1,156	1,138
Shares Outstanding	0.0%	83.00	83.00	83.00	83.00	83.00	84.00	84.00	84.00	85.00	85.00	85.00	86.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Float	-	-	-	41,325	-	-	-	28,964	-	-	-	53,418	-	-	-	27,736	-	-	-	23,369	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-8.3%	249,851	272,433	200,314	183,912	173,428	189,000	65,850	114,706	209,964	187,205	233,955	124,422	218,934	193,116	208,142	27,871	155,413	132,265	137,102	34,378	135,648
Share Based Compensation	0.0%	15,223	15,224	15,362	13,930	13,279	12,948	12,370	11,173	9,713	9,530	9,637	8,875	7,943	7,927	7,797	7,284	16,655	9,391	6,898	6,334	6,209
Cashflow From Investing	-9.3%	-30,435	-27,838	-27,470	-39,511	-49,229	-49,197	-55,086	-41,838	-44,040	-49,677	-174,663	-24,587	-15,690	-19,460	-24,556	-49,670	-95,911	-37,326	-34,085	-38,206	-39,844
Cashflow From Financing	-136.6%	-101,844	-43,038	-151,033	-146,081	-116,720	-148,829	-91,907	-13,480	-165,820	-221,726	-180,217	-129,651	398	-104,184	-161,531	16,901	-74,389	-99,751	-109,488	-2,781	-117,806
Buy Backs	5.1%	36,850	35,070	-	-	74,020	172,631	306,765	266,295	244,756	181,234	188,525	132,262	-	-	-	182,815	140,689	85,975	20,692	54,302	105,607

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IDXX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 3,660,953	$ 3,367,324	$ 3,215,360
Cost of Revenue:
Total cost of revenue	1,470,983	1,362,986	1,325,928
Gross profit	2,189,970	2,004,338	1,889,432
Expenses:
Sales and marketing	566,066	524,505	486,735
General and administrative	335,825	326,248	309,660
Research and development	190,951	254,820	161,009
Income from operations	1,097,128	898,765	932,028
Interest expense	(41,581)	(39,858)	(29,808)
Interest income	5,629	1,065	434
Income before provision for income taxes	1,061,176	859,972	902,654
Provision for income taxes	216,134	180,883	157,810
Net income	845,042	679,089	744,844
Less: Net (loss) attributable to noncontrolling interest	0	0	(1)
Net income attributable to IDEXX Laboratories, Inc. stockholders	$ 845,042	$ 679,089	$ 744,845
Earnings per Share:
Basic (in USD per share)	$ 10.17	$ 8.12	$ 8.74
Diluted (in USD per share)	$ 10.06	$ 8.03	$ 8.60
Weighted Average Shares Outstanding:
Basic (in shares)	83,066	83,623	85,200
Diluted (in shares)	83,978	84,600	86,572
Product revenue
Revenue:
Total revenue	$ 2,089,936	$ 1,928,773	$ 1,875,308
Cost of Revenue:
Total cost of revenue	717,951	656,511	656,823
Service revenue
Revenue:
Total revenue	1,571,017	1,438,551	1,340,052
Cost of Revenue:
Total cost of revenue	$ 753,032	$ 706,475	$ 669,105

IDXX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 453,932	$ 112,546
Accounts receivable, net of allowance of $9,501 in 2023 and $8,265 in 2022	457,445	400,619
Inventories	380,282	367,823
Other current assets	203,595	220,489
Total current assets	1,495,254	1,101,477
Long-Term Assets:
Property and equipment, net	702,177	649,474
Operating lease right-of-use assets	115,499	118,618
Goodwill	365,961	361,795
Intangible assets, net	84,500	97,672
Other long-term assets	496,534	417,729
Total long-term assets	1,764,671	1,645,288
TOTAL ASSETS	3,259,925	2,746,765
Current Liabilities:
Accounts payable	110,643	110,221
Accrued liabilities	478,712	433,662
Credit facility	250,000	579,000
Current portion of long-term debt	74,997	74,982
Current portion of deferred revenue	37,195	37,938
Total current liabilities	951,547	1,235,803
Long-Term Liabilities:
Deferred income tax liabilities	7,235	8,150
Long-term debt, net of current portion	622,883	694,387
Long-term deferred revenue, net of current portion	28,533	30,862
Long-term operating lease liabilities	99,671	101,239
Other long-term liabilities	65,526	67,587
Total long-term liabilities	823,848	902,225
Total liabilities	1,775,395	2,138,028
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,506 shares in 2023 and 107,193 shares in 2022; Outstanding: 83,032 shares in 2023 and 82,894 shares in 2022	10,751	10,719
Additional paid-in capital	1,569,565	1,463,215
Deferred stock units: Outstanding: 59 units in 2023 and 58 units in 2022	5,530	5,182
Retained earnings	4,444,571	3,599,529
Accumulated other comprehensive loss	(71,206)	(77,796)
Treasury stock, at cost: 24,474 shares in 2023 and 24,299 shares in 2022	(4,474,681)	(4,392,112)
Total IDEXX Laboratories, Inc. stockholders’ equity	1,484,530	608,737
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 3,259,925	$ 2,746,765

About IDEXX Laboratories Inc

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

CEO	Mr. Jonathan J. Mazelsky
WEBSITE	idexx.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	11000

IDEXX Laboratories Inc Frequently Asked Questions

What is the ticker symbol for IDEXX Laboratories Inc? What does IDXX stand for in stocks?

IDXX is the stock ticker symbol of IDEXX Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IDEXX Laboratories Inc (IDXX)?

As of Mon Apr 29 2024, market cap of IDEXX Laboratories Inc is 41.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IDXX stock?

You can check IDXX's fair value in chart for subscribers.

What is the fair value of IDXX stock?

You can check IDXX's fair value in chart for subscribers. The fair value of IDEXX Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of IDEXX Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IDXX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is IDEXX Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether IDXX is over valued or under valued. Whether IDEXX Laboratories Inc is cheap or expensive depends on the assumptions which impact IDEXX Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IDXX.

What is IDEXX Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, IDXX's PE ratio (Price to Earnings) is 49.69 and Price to Sales (PS) ratio is 11.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IDXX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on IDEXX Laboratories Inc's stock?

In the past 10 years, IDEXX Laboratories Inc has provided 0.229 (multiply by 100 for percentage) rate of return.